Vanguard Group Inc. Trims Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Vanguard Group Inc. reduced its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 2.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,703,926 shares of the company's stock after selling 160,211 shares during the period. Vanguard Group Inc. owned about 6.59% of Dyne Therapeutics worth $157,944,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Dyne Therapeutics by 5.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 134,334 shares of the company's stock worth $4,825,000 after buying an additional 6,784 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $36,000. State Street Corp lifted its position in Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company's stock valued at $130,816,000 after purchasing an additional 440,890 shares during the period. XTX Topco Ltd purchased a new stake in Dyne Therapeutics in the third quarter worth approximately $573,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Dyne Therapeutics in the 3rd quarter worth approximately $1,067,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of research reports. BMO Capital Markets started coverage on Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price target on the stock. Scotiabank assumed coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $46.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 17th. Robert W. Baird initiated coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They set an "outperform" rating and a $46.00 target price for the company. Finally, Guggenheim reiterated a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $47.46.

Insider Buying and Selling at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 6,237 shares of company stock worth $77,760 in the last quarter. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded up $0.06 during mid-day trading on Friday, reaching $7.04. The company's stock had a trading volume of 1,349,052 shares, compared to its average volume of 1,469,918. The stock has a fifty day moving average of $11.86 and a two-hundred day moving average of $21.34. The firm has a market capitalization of $796.37 million, a PE ratio of -1.98 and a beta of 1.21. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.04. Analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.